| Myelodysplastic Syndrome studied in …STUDIED_INderived10 of 1,702show all (up to 200) |
|---|
| → studied in | NCT03494569Phase 1 · suspended Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome · condition mapped CURATED_BROADER · 1,702 trials mapped (390 active) | — | — | Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03560752Phase 1 · active not recruiting CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant · condition mapped CURATED_BROADER · 1,702 trials mapped (390 active) | — | — | Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04429191Phase 1 · completed JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation · condition mapped PROBABILISTIC · 1,702 trials mapped (390 active) | — | — | Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06303193Phase 1/Phase 2 · recruiting Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms · condition mapped ALIAS · 1,702 trials mapped (390 active) | — | — | Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06484062Phase 1 · recruiting Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes · condition mapped CURATED_BROADER · 1,702 trials mapped (390 active) | — | — | Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06651229Phase 1 · active not recruiting A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms · condition mapped ALIAS · 1,702 trials mapped (390 active) | — | — | Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06904066Phase 1 · recruiting Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies · condition mapped ALIAS · 1,702 trials mapped (390 active) | — | — | Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03779854Phase 2 · active not recruiting Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant · condition mapped ALIAS · 1,702 trials mapped (390 active) | — | — | Myelodysplastic Syndrome with Excess Blasts | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564390Phase 2 · recruiting MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) · condition mapped CURATED_BROADER · 1,702 trials mapped (390 active) | — | — | Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06548230Phase 1/Phase 2 · recruiting A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) · condition mapped CURATED_BROADER · 1,702 trials mapped (390 active) | — | — | Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |